Last 1.63 GBp
Change Today 0.00 / 0.00%
Volume 2.6M
VRP On Other Exchanges
Symbol
Exchange
London
OTC US
As of 7:25 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

Open
1.63 GBp
Previous Close
1.63 GBp
Day High
1.68 GBp
Day Low
1.63 GBp
52 Week High
02/18/14 - 4.01 GBp
52 Week Low
06/23/14 - 1.05 GBp
Market Cap
16.4M
Average Volume 10 Days
2.3M
EPS TTM
-0.0060 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

10 Employees
Last Reported Date: 07/3/14

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.4K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 42.0K GBP
Compensation as of Fiscal Year 2013.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Announces First Patients Dosed with New Formulation of RPL554

Verona Pharma plc announced that a first cohort of healthy volunteers have been successfully dosed with a new proprietary, nebulised formulation of RPL554. These volunteers are part of a combined Phase I/II clinical trial profiling this new RPL554 formulation. The trial includes a single ascending dose study in healthy volunteers and 5 days multiple ascending dose study in both healthy volunteers and patients with COPD (chronic obstructive pulmonary disease). The primary objective of the study is to confirm safety, tolerability and bronchodilation with this new formulation. Up to 120 subjects are planned to be recruited to this study and the results are expected to be available in the second half of 2015. Verona Pharma is initially developing RPL554 as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting. Phase II studies to date with the drug, a novel PDE3/4 inhibitor, have been conducted in over 100 subjects. Results collectively show that the drug is a very potent bronchodilator with the ability to illicit a unique anti-inflammatory response. At the doses tested, RPL554 had a benign side effect profile, which compared favourably with existing standard treatments. The original nebulised formulation of the drug used in these initial studies was devised to provide proof-of-concept data, before developing a new formulation suitable for commercial scale-up. The new proprietary formulation of RPL554 has demonstrated very attractive properties, in addition to being viable for commercial scale-up. In pre-clinical testing, inhalation of this new formulation was better tolerated, producing significantly less irritation than the one used previously. It is expected that this will result in a significantly improved therapeutic index in patients, implying that they should be able to inhale higher doses over a shorter time interval, improving convenience and potentially compliance.

Verona Pharma plc Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 04:30 PM

Verona Pharma plc Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 04:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Sven Jan-Anders Karlsson, Chief Executive Officer and Executive Director.

Verona Pharma plc Appoints Kenneth Newman as Chief Medical Officer, Effective January 1, 2015; Announces Incorporation of Verona Pharma, Inc

Verona Pharma plc announced the appointment of Kenneth Newman, M.D., M.B.A. to the newly created position of Chief Medical Officer, with effective from 1 January 2015. Dr. Newman will be based in the US and provide his expertise to support the company's global activities. Dr. Newman is an experienced pharmaceutical and biotechnology industry executive with extensive leadership experience in clinical development, including a number of orally inhaled drugs for the treatment of respiratory disease. Dr. Newman will join Verona Pharma from Mesoblast Inc, where he was Chief Development Officer and Head of Global Clinical Development. The appointment and the creation of the US affiliate reflects the continuing focus of Verona Pharma on advancing the clinical development and commercialization of its lead pipeline drug, RPL554, a first-in-class PDE3/PDE4 inhibitor currently in phase II development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The company also announced the incorporation of its fully owned subsidiary, Verona Pharma Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 1.63 GBp 0.00

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies
 

Industry Analysis

VRP

Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.